SCHEDULE: Empery Asset Management Discloses Precision BioSciences Stake

Empery Asset Management, LP and Ryan M. Lane have reported a beneficial ownership of 7.63% in Precision BioSciences, Inc. common stock as of March 31, 2026.

Summary

• Empery Asset Management, LP, acting as the investment manager for certain funds, and Ryan M. Lane, a managing member related to the investment manager, have jointly disclosed their beneficial ownership of Precision BioSciences, Inc. common stock.
• As of March 31, 2026, the total beneficial ownership reported is 1,968,879 shares.
• This holding represents 7.63% of the company's outstanding common stock, based on 25,803,199 shares outstanding as of March 25, 2026.
• The filing is an amendment to a Schedule 13G, indicating a change in reporting status or ownership threshold.
• Both Empery Asset Management, LP and Ryan M. Lane disclaim beneficial ownership of shares held by the other, except to the extent of their respective pecuniary interests.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no direct financial performance data or strategic insights into the company's operations.

Positives

• Significant stake of 7.63% indicates a notable investment position in Precision BioSciences, Inc.
• The filing is current as of March 31, 2026, providing up-to-date information on beneficial ownership.

Negatives

• The filing does not contain specific financial performance data or strategic updates for Precision BioSciences, Inc., focusing solely on ownership disclosure.
• No explicit details are provided regarding the investment strategy or rationale behind acquiring this stake.

Risks

• Potential for increased volatility in Precision BioSciences, Inc. stock due to the significant stake held by an investment entity.
• The nature of the investment (e.g., long-term vs. short-term) is not specified, which could imply future selling pressure or continued accumulation.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Precision BioSciences, Inc.'s future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing certain ownership thresholds. This filing indicates a significant investment by Empery Asset Management in the biotechnology sector, specifically within Precision BioSciences, Inc., a company focused on gene-editing technologies.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership as a sign of confidence in the company, potentially influencing stock price. However, the intentions of the investor (activist, passive) are not clear from this filing alone.
• Management: May need to engage with Empery Asset Management, LP regarding their investment strategy and the company's performance.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from Empery Asset Management, LP and Ryan M. Lane for any changes in their beneficial ownership of Precision BioSciences, Inc. stock.
• Observe any potential strategic actions or communications from Precision BioSciences, Inc. that may be influenced by significant institutional holdings.

Key Dates

Keywords

Schedule 13G, Precision BioSciences, Empery Asset Management, Ryan M. Lane, Beneficial Ownership, Common Stock, SEC Filing, Investment Management